Literature DB >> 486226

Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidemic agent.

J Edelson, D P Benziger, A Arnold, A L Beyler.   

Abstract

The blood levels, distribution and duration of action of ciprofibrate, an orally active hypolipidemic agent, was investigated in rats. Serum concentrations of 30 micrograms of ciprofibrate/ml are associated with significant reductions in both serum cholesterol and triglycerides in rats on a hyperlipidemic diet. Increasing the plasma concentrations of ciprofibrate to 69 micrograms/ml resulted in only a modest incremental reduction in serum lipids. The distribution of radioactivity from [14C]ciprofibrate within rat tissues was not affected by prior treatment for 14 days with ciprofibrate at either 1.5 or 3.0 mg/kg/day. Varying the dosage regimen of ciprofibrate at 30 mg/kg, with medication at intervals of one, 2 or 3 days resulted in similar peak plasma levels of about 300 micrograms/ml, 4 h after medication. The half-life of ciprofibrate, during the terminal disposition phase, was about 82 h. Levels of serum cholesterol remained suppressed up to 3 days after medication with ciprofibrate was discontinued; triglyceride levels returned to control values more slowly.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 486226     DOI: 10.1016/0021-9150(79)90186-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.

Authors:  J M Makowska; F W Bonner; G G Gibson
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

2.  Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. Detection of drug activation by human liver homogenates and by human platelets.

Authors:  M Bronfman; M N Morales; L Amigo; A Orellana; L Nuñez; L Cárdenas; P C Hidalgo
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

3.  Hypocholesterolemic activity of racemic dichlorophenoxypropionic acid or its enantiomers in rats.

Authors:  F Ohta; F Gaudemer; C Lutton
Journal:  Bull Environ Contam Toxicol       Date:  1987-12       Impact factor: 2.151

4.  The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.

Authors:  N Ferry; N Bernard; N Pozet; E Gardes; G Cuisinaud; M Labeeuw; P Y Zech; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.